Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health care giant Abbott Laboratories (NYSE: ABT ) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Abbott and see what CAPS investors are saying about the stock right now.
Abbott facts
| Headquarters (founded) | Abbott Park, Ill. (1888) |
| Market Cap | $55.2 billion |
| Industry | Healthcare equipment |
| Trailing-12-Month Revenue | $40.0 billion |
| Management | Chairman/CEO Miles White (since 1999) |
| Return on Equity (average, past 3 years) | 20.6% |
| Cash / Debt | $8.5 billion / $7.1 billion |
| Dividend Yield | 1.6% |
| Competitors | Boston Scientific |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 97% of the 2,606 members who have rated Abbott believe the stock will outperform the S&P 500 going forward.
Just last week, one of those Fools, All-Star healthcarevalue, brought Abbott's solid fundamentals to our community's attention:
Price/earnings good at 10.4, reasonable market cap, Return on Invested Capital (ROIC) [13.18%] last twelve trailing months, ROIC of over [10%] going back to 2007, Low debt/equity ratio of 0.15. Abbott Laboratories has 91,000 employees and strong value in both its generic drug segment and diagnostic segments.
If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong five-star rating, Abbott may not be your top choice.
If you're looking for more long-term investing ideas, you're invited to check out The Motley Fool's brand-new special report, "The 3 Dow Stocks Dividend Investors Need." It's absolutely free, so simply click here now and get your copy today.
No comments:
Post a Comment